Maravai LifeSciences Q1 2024 Adj EPS $(0.02) Beats $(0.03) Estimate, Sales $64.179M Beat $60.548M Estimate
Maravai LifeSciences Q1 2024 Adj EPS $(0.02) Beats $(0.03) Estimate, Sales $64.179M Beat $60.548M Estimate
Maravai LifeSciences 2024年第一季度調整後每股收益美元（0.02）超過預期（0.03），銷售額爲6,417.9萬美元超過預期的6,0548萬美元
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 166.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $64.179 million which beat the analyst consensus estimate of $60.548 million by 6.00 percent. This is a 18.79 percent decrease over sales of $79.025 million the same period last year.
Maravai LifeSciences（納斯達克股票代碼：MRVI）公佈的季度虧損爲每股0.02美元（0.02美元），比分析師普遍預期的0.03美元（0.03美元）高出33.33％。與去年同期的每股收益0.03美元相比，下降了166.67％。該公司公佈的季度銷售額爲6417.9萬美元，比分析師普遍預期的6,0548萬美元高出6.00％。這比去年同期的7902.5萬美元的銷售額下降了18.79％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。